廣生堂(300436.SZ)：4項在研全球創新藥獲得專利證書或授權通知書
格隆匯 6 月 18日丨廣生堂(300436.SZ)公佈，公司自開展全球創新藥物研發以來，積極在全球範圍內開展專利申請工作，為構建全球知識產權保護體系打下了堅實的基礎。
近日，公司獲得在研全球創新藥的專利證書或授權通知書，現公告如下：
一、新型肝癌靶向藥物GST-HG161獲得日本、澳大利亞、歐洲專利授權通知書
公司新型肝癌靶向藥物GST-HG161的系列化合物已通過PCT途徑申請國際專利，經國際檢索表明滿足新穎性、創造性和實用性，已申請進入中國、美國、日本、歐洲、澳大利亞、加拿大等24個國家和地區，且已獲得中國、美國、新加坡、加拿大、南非、韓國化合物發明專利授權。
二、乙肝治療全球創新藥GST-HG141獲得韓國專利證書
公司乙肝治療全球創新藥GST-HG141的系列化合物已通過PCT途徑申請國際專利，經國際檢索表明滿足新穎性、創造性和實用性，已申請進入中國、美國、日本、歐洲等20多個國家和地區，且已獲得中國化合物發明專利授權。
三、乙肝治療全球創新藥 GST-HG121、GST-HG131獲得中國、韓國、歐洲等專利證書或授權通知書
公司乙肝治療全球創新藥GST-HG121、GST-HG131的系列化合物已通過PCT途徑申請國際專利，經國際檢索表明滿足新穎性、創造性和實用性，GST-HG121已申請進入中國、美國、日本、歐洲等20個國家和地區，GST-HG131已申請進入中國、美國、日本、歐洲等10多個國家和地區。
四、非酒精性脂肪肝病及肝纖維化可逆轉新藥GST-HG151獲得韓國、南非專利授權，獲得加拿大專利授權通知
公司非酒精性脂肪肝病及肝纖維化可逆轉新藥GST-HG151的系列化合物已申請PCT國際專利，經國際檢索表明滿足新穎性、創造性和實用性，已申請進入中國、美國、日本、歐洲、澳大利亞、加拿大等19個國家和地區，且已獲得中國、日本化合物發明專利授權。
創新藥發明專利的授權有利於公司完善知識產權保護體系，發揮自主知識產權優勢，提升核心競爭力。新藥研發具有周期長、風險大、投入高的特點。公司將按照相關規定履行信息披露義務，敬請投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
